Myths and mysteries about staging hepatic fibrosis by fibroscan.

about

Myths and mysteries about staging hepatic fibrosis by fibroscan.

Item

http://www.wikidata.org/entity/Q42736140

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@en

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@nl

type

Item

label

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@en

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@nl

prefLabel

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@en

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@nl

P1476

Myths and mysteries about staging hepatic fibrosis by fibroscan.

@en

P2093

Arun J Sanyal

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents

Liver stiffness: a novel parameter for the diagnosis of liver disease.

Liver Hemangioma Might Lead to overestimation of Liver Fibrosis by Fibroscan; A Missed Issue in Two Cases.

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.

Acute viral hepatitis increases liver stiffness values measured by transient elastography.

Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.

Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution.

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.

P304

780-782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1016/J.CGH.2014.10.030

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Raj Vuppalanchi

P577

2014-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25451885

http://www.w3.org/2001/XMLSchema#string

P932

4900149

http://www.w3.org/2001/XMLSchema#string